Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 6, 2013, Pages 998-1008

  Stoehr, Christine G ^a   Buettner Herold, Maike ^a   Kamphausen, Esther ^b   Bertz, Simone ^a   Hartmann, Arndt ^a   Seliger, Barbara ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Erap; Hla class I; Immune escape; Renal cell carcinoma

Indexed keywords

AMINOPEPTIDASE; ERAP1 PROTEIN, HUMAN; ERAP2 PROTEIN, HUMAN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; TUMOR MARKER;

ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; ENDOPLASMIC RETICULUM; ENZYMOLOGY; ERAP; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HLA CLASS I; HUMAN; IMMUNE ESCAPE; IMMUNOLOGY; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR ESCAPE;

ERAP; HLA CLASS I; IMMUNE ESCAPE; RENAL CELL CARCINOMA;

AMINOPEPTIDASES; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; KIDNEY; KIDNEY NEOPLASMS; MALE; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84882947492     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. van Endert P. Post-proteasomal and proteasome- independent generation of MHC class I ligands. Cell Mol Life Sci 2011; 68: 1553- 1567.
2. Jensen PE. Recent advances in antigen processing and presentation. Nat Immunol 2007; 8: 1041-1048.
3. Wearsch PA and Cresswell P. The quality control of MHC class I peptide loading. Curr Opin Cell Biol 2008; 20: 624-631.
4. Yan J, Parekh VV, Mendez-Fernandez Y, Olivares-Villagomez D, Dragovic S, Hill T, Roopenian DC, Joyce S, and Van Kaer L. In vivo role of ERassociated peptidase activity in tailoring peptides for presentation by MHC class Ia, and class Ib molecules. J Exp Med 2006; 203: 647-659.
5. Rock KL, Farfan-Arribas DJ, and Shen L. Proteases in MHC class I presentation, and crosspresentation. J Immunol 2010; 184: 9-15.
6. Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, and Goldberg AL. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class Ipresented peptides. Nat Immunol 2002; 3: 1169-1176.
7. York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, and Rock KL. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol 2002; 3: 1177-1184.
8. York IA, Brehm MA, Zendzian S, Towne CF, and Rock KL. Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo, and plays an important role in immunodominance. Proc Natl Acad Sci U S A 2006; 103: 9202-9207.
9. Hearn A, York IA, and Rock KL. The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J Immunol 2009; 183: 5526-5536.
10. Chang SC, Momburg F, Bhutani N, and Goldberg AL. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc Natl Acad Sci U S A 2005; 102: 17107-17112.
11. Hammer GE, Gonzalez F, Champsaur M, Cado D, and Shastri N. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 2006; 7: 103-112.
12. Hammer GE, Gonzalez F, James E, Nolla H, and Shastri N. In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable, and highly immunogenic peptides. Nat Immunol 2007; 8: 101-108.
13. Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, Chang CH, Harndahl M, Weimershaus M, Gerstoft J, Akkad N, Klenerman P, Fugger L, Jones EY, McMichael AJ, Buus S, Schild H, van Endert P, and Iversen AK. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 2009; 10: 636-646.
14. Cifaldi L, Lo Monaco E, Forloni M, Giorda E, Lorenzi S, Petrini S, Tremante E, Pende D, Locatelli F, Giacomini P, and Fruci D. Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. Cancer Res 2011; 71: 1597-1606.
15. Fruci D, Giacomini P, Nicotra MR, Forloni M, Fraioli R, Saveanu L, van Endert P, and Natali PG. Altered expression of endoplasmic reticulum aminopeptidases ERAP1, and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol 2008; 216: 742-749.
16. Hattori A, Kitatani K, Matsumoto H, Miyazawa S, Rogi T, Tsuruoka N, Mizutani S, Natori Y, and Tsujimoto M. Characterization of recombinant human adipocyte-derived leucine aminopeptidase expressed in Chinese hamster ovary cells. J Biochem 2000; 128: 755-762.
17. Shido F, Ito T, Nomura S, Yamamoto E, Sumigama S, Ino K, Itakura A, Hattori A, Tsujimoto M, Mizutani S, and Kikkawa F. Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells. Endocrinology 2006; 147: 1780-1788.
18. Shibata D, Ando H, Iwase A, Nagasaka T, Hattori A, Tsujimoto M, and Mizutani S. Distribution of adipocyte-derived leucine aminopeptidase (A-LAP)/ER-aminopeptidase (ERAP)-1 in human uterine endometrium. J Histochem Cytochem 2004; 52: 1169-1175.
19. Watanabe Y, Shibata K, Kikkawa F, Kajiyama H, Ino K, Hattori A, Tsujimoto M, and Mizutani S. Adipocyte-derived leucine aminopeptidase suppresses angiogenesis in human endometrial carcinoma via renin-angiotensin system. Clin Cancer Res 2003; 9: 6497-6503.
20. Shibata K, Kikkawa F, Mizokami Y, Kajiyama H, Ino K, Nomura S, and Mizutani S. Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma. Tumour Biol 2005; 26: 9-16.
21. Kamphausen E, Kellert C, Abbas T, Akkad N, Tenzer S, Pawelec G, Schild H, van Endert P, and Seliger B. Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Cancer Immunol Immunother 2010; 59: 1273-1284.
22. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, and Fleuren GJ. Association of antigen processing machinery, and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2008; 57: 197-206.
23. Goto Y, Tanji H, Hattori A, and Tsujimoto M. Glutamine-181 is crucial in the enzymatic activity, and substrate specificity of human endoplasmic-reticulum aminopeptidase-1. Biochem J 2008; 416: 109-116.
24. Forloni M, Albini S, Limongi MZ, Cifaldi L, Boldrini R, Nicotra MR, Giannini G, Natali PG, Giacomini P, and Fruci D. NF-kappaB,, and not MYCN, regulates MHC class I, and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. Cancer Res 2010; 70: 916-924.
25. Saveanu L, Carroll O, Hassainya Y, and van Endert P. Complexity, contradictions,, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation. Immunol Rev 2005; 207: 42-59.
26. Stam NJ, Spits H, and Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986; 137: 2299-2306.
27. Eble JN, Sauter G, Epstein JI, and Sesterhenn IA. Pathology, and Genetics of Tumours of the Urinary System, and Male Genital Organs. Lyon: IARC Press; 2004.
28. Sobin LH, and Wittekind C. TNM Classification of Malignant Tumours. Hoboken, New Jersey: John Wiley & Sons, 2002.
29. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stohr R, Simon R, Sauter G, Leibiger H, Essers L, Weber B, Hermann K, Rosenthal A, Hartmann A, and Dahl E. Loss of SFRP1 is associated with breast cancer progression, and poor prognosis in early stage tumors. Int J Oncol 2004; 25: 641-649.
30. Atkins D, Ferrone S, Schmahl GE, Storkel S, and Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J Urol 2004; 171: 885-889.
31. Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, and Hartmann A. Association of HLA class I antigen abnormalities with disease progression, and early recurrence in prostate cancer. Cancer Immunol Immunother 2010; 59: 529-540.
32. Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, and Huber C. Reduced membrane major histocompatibility complex class I density, and stability in a subset of human renal cell carcinomas with low TAP, and LMP expression. Clin Cancer Res 1996; 2: 1427-1433.
33. Fruci D, Ferracuti S, Limongi MZ, Cunsolo V, Giorda E, Fraioli R, Sibilio L, Carroll O, Hattori A, van Endert PM, and Giacomini P. Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors, and in leukemia/ lymphoma, carcinoma,, and melanoma cell lines. J Immunol 2006; 176: 4869-4879.
34. Saenz-Lopez P, Gouttefangeas C, Hennenlotter J, Concha A, Maleno I, Ruiz-Cabello F, Cozar JM, Tallada M, Stenzl A, Rammensee HG, Garrido F, and Cabrera T. Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens 2010; 75: 110-118.
35. Dovhey SE, Ghosh NS, and Wright KL. Loss of interferon-gamma inducibility of TAP1, and LMP2 in a renal cell carcinoma cell line. Cancer Res 2000; 60: 5789-5796.